ENABLR serves the most vulnerable patients by our unique offering of safe, more durable and more potent T cell therapy

ENABLR (ENineered Antigen Blinded Receptor) T-cell platform  are allogenic T-cells engineered to lose antigen recognition by removing the variable domains in the α and β chains of the T-cell receptor; however they retain the CD3 dependent downstream activation machinery.

ENABLR cells therefore are potently cytotoxic to tumour cells when given in conjunction with T-cell engaging bispecific antibodies (TCE) . Due to the lack of antigen recognition GvHD is reliable prevented; the cells can therefore be universally applied.

The ENABLR platform is inherently safe, as the cells are immunologically silent without addition of a bi-specific antibody. Safety is further increased by a suicide switch, which can be activated in case of uncontrolled proliferation. As the technology is not limited by the kind of tumour associated antigen (TAA), ENABLR cells can be also combined with multiple TCEs, and will be activated by them simultaneously.

ENABLR is therefore a first in class technology which combines the benefits of adaptive T-cell transfer with CD3-based T-cell activation using bi-specific antibodies. The technology relieves the dependence of TCEs on the pre-existing landscape of patient T-cells, which in many cases have an abundance of exhausted phenotype due to high tumour burden and persistent activation by tumour antigen. As the cells are derived from healthy donors, they present a consistent and highly activatable population of tumour naive T-cells.